Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225341 · ClinicalTrials.gov registry record · NA
Botulinum Toxin A for Herpes Labialis
A NA study, sponsored by DeNova Research.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01225341 is a NA study that was terminated before completion, run by DeNova Research. The registered enrollment target is 20 participants.
The verdict
NCT01225341, a NA study, was terminated before completion, sponsored by DeNova Research.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.
Interventions
- DRUG onabotulinumtoxinA
- OTHER Bacteriostatic normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225341
The ClinicalTrials.gov registry entry for NCT01225341 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DeNova Research, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which onabotulinumtoxinA is the first listed.
NCT01225341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225341 about?
NCT01225341 is a clinical study titled "Botulinum Toxin A for Herpes Labialis". The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.
What is the current status of trial NCT01225341?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2010-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01225341?
The interventions under investigation include: onabotulinumtoxinA (DRUG), Bacteriostatic normal saline (OTHER).
Who is sponsoring clinical trial NCT01225341?
This trial is sponsored by DeNova Research, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.